Navtemadlin’s oral MDM2 approach offers disease-modifying potential in myelofibrosis, especially after poor JAK inhibitor response. Monotherapy, ruxolitinib add-on use and development across blood and ...
Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, followed by radiation and chemotherapy. The prognosis is poor even with ...
Promising Biomarker Reductions: Treatment with the MDM2 inhibitor navtemadlin led to significant reductions in key biomarkers of disease severity, including circulating CD34+ cells, a hallmark of ...
Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen's growing Oncology portfolio Navtemadlin, an oral MDM2 ...
Myelofibrosis causes anemia, splenomegaly, and other symptoms, creating unmet treatment needs. The POIESIS trial explores navtemadlin as an add-on to Jakafi for suboptimal responders. Navtemadlin ...
Ipsen IPN0.38%increase; up pointing triangle said it agreed to buy Kartos Therapeutics in a deal valued at up to $1.75 billion that seeks to strengthen the French drugmaker’s pipeline of cancer ...
Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.
Dana-Farber Cancer Institute authors: Veronica Rendo, PhD, Eudocia Q. Lee, MD, MPH, Veronica Rendo, PhD Patrick Y. Wen, MD, Keith L. Ligon, MD, PhD, Rameen Beroukhim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results